What they were paid
Foghorn Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $85,351 | $0 | $91,970 | $0 | $177,321 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Foghorn Therapeutics Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-193928, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Foghorn Therapeutics pays directors a $40,000 cash retainer.
Committees
FY2025 · as the proxy prints themCompensation · Nominating/Governance (Chair)
The rest of the Foghorn Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Adrian Gottschalk | Director | $0 |
| B. Lynne Parshall | Independent Director | $151,754 |
| Balkrishan (Simba) Gill, Ph.D | Independent Director | $151,037 |
| Ian F. Smith | Independent Director | $131,970 |
| Michael Mendelsohn, M.D | Independent Director | $147,321 |
| Neil J. Gallagher, M.D., Ph.D | Independent Director | $193,002 |
| Scott Biller, Ph.D | Independent Director | $136,754 |
| Stuart Duty | Independent Director | $194,669 |
| Thomas J. Lynch Jr., M.D | Independent Director | $140,087 |
The full Foghorn Therapeutics compensation record
free company briefThis page is one director within Foghorn Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat